CY1112614T1 - Αγωγη με κλαδριβινη για τη θεραπεια πολλαπλης σκληρυνσης - Google Patents

Αγωγη με κλαδριβινη για τη θεραπεια πολλαπλης σκληρυνσης

Info

Publication number
CY1112614T1
CY1112614T1 CY20121100358T CY121100358T CY1112614T1 CY 1112614 T1 CY1112614 T1 CY 1112614T1 CY 20121100358 T CY20121100358 T CY 20121100358T CY 121100358 T CY121100358 T CY 121100358T CY 1112614 T1 CY1112614 T1 CY 1112614T1
Authority
CY
Cyprus
Prior art keywords
treatment
multiple sclerosis
cladribine
medicament
treatments
Prior art date
Application number
CY20121100358T
Other languages
Greek (el)
English (en)
Inventor
Luca Giampiero De
Arnaud Ythier
Alain Munafo
Maria Lopez-Bresnahan
Original Assignee
Merck Serono Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36227798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1112614(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Serono Sa filed Critical Merck Serono Sa
Publication of CY1112614T1 publication Critical patent/CY1112614T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/215IFN-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CY20121100358T 2004-12-22 2012-04-11 Αγωγη με κλαδριβινη για τη θεραπεια πολλαπλης σκληρυνσης CY1112614T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63866904P 2004-12-22 2004-12-22
EP04106909 2004-12-22
EP05823474A EP1827461B1 (en) 2004-12-22 2005-12-20 Cladribine regimen for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
CY1112614T1 true CY1112614T1 (el) 2016-02-10

Family

ID=36227798

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20121100358T CY1112614T1 (el) 2004-12-22 2012-04-11 Αγωγη με κλαδριβινη για τη θεραπεια πολλαπλης σκληρυνσης
CY20181100065T CY1119790T1 (el) 2004-12-22 2018-01-18 Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
CY2018006C CY2018006I1 (el) 2004-12-22 2018-02-28 Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας

Family Applications After (2)

Application Number Title Priority Date Filing Date
CY20181100065T CY1119790T1 (el) 2004-12-22 2018-01-18 Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
CY2018006C CY2018006I1 (el) 2004-12-22 2018-02-28 Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας

Country Status (25)

Country Link
US (2) US7713947B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (7) EP1827461B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (7) JP5795456B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20070091662A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR052830A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU2005318190B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0517132B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (2) CA3087419C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (3) CY1112614T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (3) DK4070800T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA015799B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (2) ES3007339T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI4070800T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR18C1008I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20120228T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (3) HUE070333T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL183930A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (3) LT3332789T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LUC00064I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2007007610A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (1) NO20073813L (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (4) PL1827461T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG160391A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (3) SI3332789T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2006067141A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK4070800T3 (da) 2004-12-22 2025-01-02 Merck Serono Sa Cladribinkur til behandling af multipel sklerose
PL2026832T3 (pl) 2006-05-24 2012-08-31 Merck Serono Sa Skojarzony reżim interferonu beta i kladrybiny do leczenia stwardnienia rozsianego
EP2343074A1 (en) 2009-12-23 2011-07-13 Merck Serono S.A. Use of purine analogues for treating airway diseases
WO2011117267A1 (en) 2010-03-24 2011-09-29 Merck Serono Sa Cladribine treatment of multiple sclerosis in patient groups defined by genotype
EP2428201A1 (en) 2010-09-08 2012-03-14 Merck Serono S.A. Oral administration of nucleoside monophosphates
WO2012097867A1 (en) 2011-01-18 2012-07-26 Synthon Bv Cladribine particles and pharmaceutical compositions comprising them
GB201401465D0 (en) * 2014-01-29 2014-03-12 Roach Arthur H Use of cladribine for treating autoimmune inflammatory disease
GB2564717A (en) 2017-07-21 2019-01-23 Chord Therapeutics S A R L Use of cladribine for treating autoimmune neuromuscular disease
BR112020010282A2 (pt) * 2017-11-24 2020-11-17 Merck Patent Gmbh regime de cladribina para uso no tratamento de formas progressivas de esclerose múltipla
GB2601786A (en) 2020-12-10 2022-06-15 Chord Therapeutics S A R L Use of cladribine for treating immune brain disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1269659A (en) 1984-08-06 1990-05-29 Brigham Young University Method for the production of 2'-deoxyadenosine compounds
US5310732A (en) 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
US4964848A (en) * 1988-06-27 1990-10-23 Bloom Philip M Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression
US5208327A (en) 1991-12-18 1993-05-04 Ortho Pharmaceutical Corporation Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine
US5641757A (en) 1994-12-21 1997-06-24 Ortho Pharmaceutical Corporation Stable 2-chloro-2'-deoxyadenosine formulations
CA2208484C (en) 1994-12-22 2008-09-23 Ortho Pharmaceutical Corporation Soluble 2-chloro-2'-deoxyadenosine formulations
US6194395B1 (en) 1999-02-25 2001-02-27 Orthro-Mcneil Pharmaceutical, Inc. Cyclodextrin cladribine formulations
WO2000064918A1 (en) 1999-04-28 2000-11-02 Sterrenbeld Biotechnologie North America, Inc. METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE
DE10237146A1 (de) * 2002-08-13 2004-03-04 Medac Gesellschaft für klinische Spezialpräparate mbH Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose
JP4757632B2 (ja) 2002-09-25 2011-08-24 ブリガム ヤング ユニバーシティー 2’−デオキシグアノシンから2−クロロ−2’−デオキシアデノシンを調製する方法
GB2394658A (en) * 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
JP2006518725A (ja) * 2003-02-25 2006-08-17 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 脱髄疾患におけるリバビリンとインターフェロンベータの併用
KR20060011943A (ko) 2003-03-28 2006-02-06 아이박스 코포레이션 향상된 경구 및 경점막 수송용 클라드리빈 제형
SG175450A1 (en) 2003-03-28 2011-11-28 Ares Trading Sa Oral formulations of cladribine
DK4070800T3 (da) 2004-12-22 2025-01-02 Merck Serono Sa Cladribinkur til behandling af multipel sklerose
PL2026832T3 (pl) * 2006-05-24 2012-08-31 Merck Serono Sa Skojarzony reżim interferonu beta i kladrybiny do leczenia stwardnienia rozsianego

Also Published As

Publication number Publication date
JP6092945B2 (ja) 2017-03-08
HUE070333T2 (hu) 2025-05-28
EP2263678A3 (en) 2011-04-27
JP2016138128A (ja) 2016-08-04
EP2263678A2 (en) 2010-12-22
JP6430554B2 (ja) 2018-11-28
US20090081163A1 (en) 2009-03-26
JP5908863B2 (ja) 2016-04-26
FI4070800T3 (fi) 2025-01-14
CA2588966C (en) 2020-07-21
PL1827461T3 (pl) 2012-07-31
JP2008524313A (ja) 2008-07-10
BRPI0517132B8 (pt) 2021-05-25
EA015799B1 (ru) 2011-12-30
EP3332789A1 (en) 2018-06-13
KR20070091662A (ko) 2007-09-11
ES2921858T3 (es) 2022-09-01
FR18C1008I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-03-30
EP2275110A2 (en) 2011-01-19
CY2018006I2 (el) 2018-06-27
DK3332789T3 (da) 2022-07-11
DK4070800T3 (da) 2025-01-02
EP2275110B1 (en) 2013-07-10
LTC2805723I2 (lt) 2022-04-25
AR052830A1 (es) 2007-04-04
SI4070800T1 (sl) 2025-03-31
EP3332789B1 (en) 2022-04-06
JP5795456B2 (ja) 2015-10-14
EP2805723B1 (en) 2018-01-17
US7713947B2 (en) 2010-05-11
SG160391A1 (en) 2010-04-29
PL2805723T3 (pl) 2018-04-30
CA3087419C (en) 2023-03-07
EP2275110A3 (en) 2011-04-27
BRPI0517132B1 (pt) 2020-02-18
EP4070800B1 (en) 2024-10-16
EP4070800A1 (en) 2022-10-12
EP4523753A2 (en) 2025-03-19
JP2017101061A (ja) 2017-06-08
ES3007339T3 (en) 2025-03-19
JP2015180685A (ja) 2015-10-15
WO2006067141A1 (en) 2006-06-29
EP2805723A1 (en) 2014-11-26
NO20073813L (no) 2007-09-21
CA2588966A1 (en) 2006-06-29
LT3332789T (lt) 2022-07-25
DK2805723T3 (da) 2018-01-29
EP1827461A1 (en) 2007-09-05
US8377903B2 (en) 2013-02-19
IL212421A0 (en) 2011-06-30
SI3332789T1 (sl) 2022-08-31
HUE059133T2 (hu) 2022-10-28
SI2805723T1 (en) 2018-02-28
AU2011200768A1 (en) 2011-03-17
AU2005318190A1 (en) 2006-06-29
LT4070800T (lt) 2025-01-10
BRPI0517132A (pt) 2008-09-30
IL212421A (en) 2014-01-30
EA200701221A1 (ru) 2008-02-28
PL3332789T3 (pl) 2022-08-22
CA3087419A1 (en) 2006-06-29
AU2005318190B2 (en) 2010-11-25
HUS1800009I1 (hu) 2018-05-02
PL4070800T3 (pl) 2025-03-10
LTPA2018503I1 (lt) 2018-03-12
LUC00064I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-03-28
IL183930A0 (en) 2007-10-31
LUC00064I1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2018-02-14
JP2018165271A (ja) 2018-10-25
JP6290962B2 (ja) 2018-03-07
EP2263678B1 (en) 2014-06-11
JP2013216664A (ja) 2013-10-24
MX2007007610A (es) 2007-08-03
AU2011200768B2 (en) 2012-09-13
HRP20120228T1 (hr) 2012-04-30
JP2020193206A (ja) 2020-12-03
FR18C1008I2 (fr) 2019-03-01
EP4523753A3 (en) 2025-05-28
CY1119790T1 (el) 2018-06-27
EP1827461B1 (en) 2012-02-29
US20100203017A1 (en) 2010-08-12
CY2018006I1 (el) 2018-06-27

Similar Documents

Publication Publication Date Title
CY1112614T1 (el) Αγωγη με κλαδριβινη για τη θεραπεια πολλαπλης σκληρυνσης
CY1109656T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
CY1117217T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης
CY1117615T1 (el) Ενωσεις θειαζολης σουλφοναμιδης και οξαζολης
CY1113352T1 (el) Ενωση σπειρο-δακτυλιου και χρηση αυτης για ιατρικους σκοπους
CY1108183T1 (el) Θειαζολυλο-διυδρο-ινδαζολια
CY1111148T1 (el) Ιμιδαζο- και τριαζολοπυριδινες ως αναστολεις της 11β-υδροξυστεροειδικης αφυδρογονασης τυπου i
CL2012002526A1 (es) Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca.
SV2004001690A (es) Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos
DE602005023185D1 (de) Prodrugs mit neuen biospaltbaren verbindern
SE0301653D0 (sv) Novel compounds
CY1112369T1 (el) 2-μεθυλο-2-[4-(3-μεθυλο-2-οξο-8-κινολιν-3-υλο-2,3-διϋδρο-ιμιδαζο[4,5-c]κινολινυλο)-φαινυλο]προπιονιτριλιο ως αναστολεας λιπιδικης κινασης
RS54123B1 (en) THERAPEUTIC COMBINATION CONTAINING DOLUTEGRAVIR, ABACAVIR AND LAMIVUDINE
CY1110419T1 (el) Τρικυκλικες ενωσεις με βαση το 1,6-διυδρο-1,3,5,6-tetpaaza-as-ινδακενιο και φαρμακευτικες συνθεσεις που τις περιεχουν ως αναστολεις της ενζυμικης ενεργοτητας της ικκ
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
CY1110127T1 (el) Υποκατεστημενες 1-προπιολυλο-πιπεραζινες με χημικη συγγενεια για τον υποδοχεα mglur5 για τη θεραπεια καταστασεων πονου
CL2007000595A1 (es) Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras.
CY1113059T1 (el) Οργανικες ενωσεις
CY1119402T1 (el) Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες
CY1107230T1 (el) Υποκατεστημενες ενωσεις 1-φαιναιθυλοπιπεριδινης, οι οποιες μεταξυ αλλων χρησιμοποιουνται σαν αναλγητικα
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
CY1108916T1 (el) Υποκαθιστουμενες πυρρολες, οι ενωσεις που τις περιεχουν, διαδικασια παρασκευης και χρηση τους
EA200602281A1 (ru) Гетероарилсульфоны и сульфонамиды и их терапевтические применения
ATE391489T1 (de) Haarbehandlungszusammensetzungen
DE502008002979D1 (de) Arylsulfonamide mit analgetischer wirkung